PreludeDx Email Format

Biotechnology ResearchCalifornia, United States51-200 Employees

PreludeDx is a biotechnology company focused on precision diagnostics for early-stage breast cancer. Its initial diagnostic, DCISionRT, grew out of more than a decade of research and development and was created after licensing technology from the University of California, San Francisco in 2009. The DCISionRT test is designed to quantify a patient’s risk of recurrence and help determine appropriate treatment for ductal carcinoma in situ.

Based in Laguna Hills, California, PreludeDx serves patients and healthcare providers by offering tools to manage early-stage breast cancer and inform clinical decision-making. In April 2026, the company announced that the FDA granted Breakthrough Device Designation to its AidaBreast test for early-stage invasive breast cancer, marking a notable regulatory milestone for its diagnostic portfolio.

Get verified PreludeDx emails free

Company overview Employee directory